This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Northstar Announces New Product Aimed At Dominating The Multi-billion Dollar Pet Healthcare Industry





HOLBROOK, N.Y., Dec. 6, 2012 /PRNewswire/ -- Northstar Global Business Services, Inc. Symbol (OTCPink: MDIN), today announced plans to release "StemEnrich© For pets", the first stem cell replacement therapy product made specifically for house pets. The new product is a welcomed addition to the company's existing product line which includes the popular products, "Snorenz®", and "Good Night's Sleep®", both of which have been very successful, selling millions of units annually in past years. These products have been on the shelves of large retail chains like Wal-Mart®, Walgreens® and CVS®, and after a two-year break, have already begun shipping to retailers once again with the goal of being distributed through every major retail chain in the US.

We all know pet owners will do and spend just about anything for their pets. Even through a recession, the pet food, food supplement and pet health products industries have grown 6-7% every year reaching over a half trillion dollars annually. Like StemIntense©, another Northstar Product which starts shipping in just a few weeks, StemEnrich© uses special extracts from all natural aquatic algae to increase free flowing adult stem cells in the body of both humans and animals. With vitamins and nutrients specific to domestic dogs and cats added, StemEnrich© can increase the length and quality of life of pets substantially. Independent studies show that these compounds increase muscle and bone strength, decrease the chances of injuries, kill pain, increase eyesight and hearing performance, and give animals more endurance. It's also been shown to increase memory and create an overall happier and clearer mental state according to laboratory tests.

Packaged as a one-a-day treat, StemEnrich will also speed up recovery and healing of injuries, a factor very important since our pets cannot tell us what ails them. "If I knew that giving my dog a small treat every day would make her live longer, and be more comfortable, I would have been making this product years ago. It's especially important for rare breeds who typically have many ailments as a result of genetics," said Nicholas Chieco, Northstar's CEO. "This is basically a one size fits all cure for pets, and I am really proud to think we may help millions of pets live happier lives. It makes you feel really good about what you are doing," he added.

The company plans to release StemEnrich© later in the year through already existing retail channels, most of which have pet sections, making distribution an extension of what the company is already doing, not an entirely new venture. The product will retail for about $9.99 for a 30-day supply and earns the company an estimated $4.25 per unit. The biggest challenge the company faces is manufacturing enough products for the current demand, a problem CEO Nick Chieco is happy to have. Initial projections based on current interest have 2013 projected sales at well over two million units right now, but according to Chieco that number will likely go up, and possibly even surpass the company's other products in sales revenue within three years. Northstar aims to be a major leader in alternative health products, and at their current rate as long as they can line up the manufacturing to fulfill orders, there seems to be no ceiling on the potential earnings for the company's next fiscal year, and no stopping Northstar from supplying alternative health products and supplements to every major retail chain in the world.

About Northstar

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,390.32 -288.38 -1.63%
S&P 500 2,033.03 -24.06 -1.17%
NASDAQ 4,696.9260 -74.8370 -1.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs